KR20180127407A - 암 요법용 조작된 trail - Google Patents

암 요법용 조작된 trail Download PDF

Info

Publication number
KR20180127407A
KR20180127407A KR1020187029745A KR20187029745A KR20180127407A KR 20180127407 A KR20180127407 A KR 20180127407A KR 1020187029745 A KR1020187029745 A KR 1020187029745A KR 20187029745 A KR20187029745 A KR 20187029745A KR 20180127407 A KR20180127407 A KR 20180127407A
Authority
KR
South Korea
Prior art keywords
ser
gly
leu
lys
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020187029745A
Other languages
English (en)
Korean (ko)
Inventor
다이아나 훙-이 카이 마르칸토니오
스티븐 엘 사진스키
비르기트 엠 쇼에베를
에릭 엠 탐
Original Assignee
메리맥 파마슈티컬즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메리맥 파마슈티컬즈, 인크. filed Critical 메리맥 파마슈티컬즈, 인크.
Publication of KR20180127407A publication Critical patent/KR20180127407A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020187029745A 2016-03-16 2017-03-16 암 요법용 조작된 trail Withdrawn KR20180127407A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662309352P 2016-03-16 2016-03-16
US62/309,352 2016-03-16
US201662323501P 2016-04-15 2016-04-15
US62/323,501 2016-04-15
US201762445556P 2017-01-12 2017-01-12
US62/445,556 2017-01-12
PCT/US2017/022789 WO2017161173A1 (en) 2016-03-16 2017-03-16 Engineered trail for cancer therapy

Publications (1)

Publication Number Publication Date
KR20180127407A true KR20180127407A (ko) 2018-11-28

Family

ID=58413224

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187029745A Withdrawn KR20180127407A (ko) 2016-03-16 2017-03-16 암 요법용 조작된 trail

Country Status (10)

Country Link
US (1) US20190077870A1 (enExample)
EP (1) EP3430034A1 (enExample)
JP (1) JP2019518713A (enExample)
KR (1) KR20180127407A (enExample)
CN (1) CN108884142A (enExample)
AU (1) AU2017234679A1 (enExample)
CA (1) CA3017622A1 (enExample)
IL (1) IL261267A (enExample)
MX (1) MX2018011219A (enExample)
WO (1) WO2017161173A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022080865A3 (ko) * 2020-10-13 2022-08-11 신동준 반려견의 항암용 재조합 단백질 및 이를 포함하는 반려견을 위한 항암용 조성물

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017066963A1 (zh) * 2015-10-22 2017-04-27 成都华创生物技术有限公司 一种TRAIL双靶点突变蛋白MuR6S4TR、其制备方法及其应用
KR20190017804A (ko) * 2016-06-13 2019-02-20 메리맥 파마슈티컬즈, 인크. 환자를 선별하고 trail-기반 치료제 또는 사멸 수용체 효능제로 치료하는 방법
CN109125709B (zh) * 2018-08-23 2021-10-22 成都华创生物技术有限公司 Trail突变体在制备治疗痤疮药物中的应用及一种制剂

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
JPH0822239B2 (ja) * 1988-07-07 1996-03-06 株式会社蛋白工学研究所 変異ヒト腫傷壊死因子
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
EP1194555B1 (en) * 1999-06-28 2012-09-26 Genentech, Inc. Methods for making apo-2 ligand using divalent metal ions
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
US6725230B2 (en) 2000-07-18 2004-04-20 Aegis Analytical Corporation System, method and computer program for assembling process data of multi-database origins using a hierarchical display
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
PT1534335E (pt) 2002-08-14 2012-02-28 Macrogenics Inc Anticorpos específicos de fcγriib e processos para a sua utilização
CA2832136C (en) 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
ATE480562T1 (de) 2002-10-15 2010-09-15 Facet Biotech Corp Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
GB0328261D0 (en) * 2003-12-05 2004-01-07 Univ Groningen Improved cytokine design
JP4762156B2 (ja) 2004-01-12 2011-08-31 アプライド モレキュラー エボリューション，インコーポレイテッド Ｆｃ領域変異体
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
BRPI0514068B8 (pt) 2004-08-04 2021-05-25 Applied Molecular Evolution Inc anticorpo anti-cd20, e, composição farmacêutica
GB0724532D0 (en) * 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
PL2604693T3 (pl) * 2008-07-21 2016-09-30 Jednołańcuchowe cząsteczki TNFSF
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
EP2437767B1 (en) * 2009-06-01 2015-07-08 MedImmune, LLC Molecules with extended half-lives and uses thereof
WO2011139681A1 (en) 2010-04-26 2011-11-10 Merrimack Pharmaceuticals Assays for anti-drug antibodies in the presence of abundant endogenous protein counterpart of the drug
EP2468764A1 (en) * 2010-12-24 2012-06-27 Rijksuniversiteit te Groningen TNF family ligand variants
JP6047142B2 (ja) * 2011-04-01 2016-12-21 ウニヴェルズィテート シュトゥットガルト 抗体結合ドメインを有する組換えｔｎｆリガンドファミリーメンバーポリペプチドおよびそれらの使用
CN102863537A (zh) * 2011-07-06 2013-01-09 江苏靶标生物医药研究所有限公司 一种肿瘤靶向性肿瘤坏死因子相关凋亡配体变体及其应用
NO2776305T3 (enExample) * 2014-04-23 2018-01-27
WO2016146818A1 (en) * 2015-03-18 2016-09-22 Universität Stuttgart Single-chain tnf ligand family molecules and fusion proteins and derivatives thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022080865A3 (ko) * 2020-10-13 2022-08-11 신동준 반려견의 항암용 재조합 단백질 및 이를 포함하는 반려견을 위한 항암용 조성물

Also Published As

Publication number Publication date
IL261267A (en) 2018-10-31
CA3017622A1 (en) 2017-09-21
CN108884142A (zh) 2018-11-23
MX2018011219A (es) 2019-01-10
JP2019518713A (ja) 2019-07-04
EP3430034A1 (en) 2019-01-23
WO2017161173A1 (en) 2017-09-21
US20190077870A1 (en) 2019-03-14
AU2017234679A1 (en) 2018-08-30

Similar Documents

Publication Publication Date Title
JP7587656B2 (ja) Ｐｄ－ｌ１及びｃｄ１３７に結合する抗体分子
KR102427192B1 (ko) 항-인간 4-1bb 항체 및 그의 용도
US11377477B2 (en) PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereof
TWI853809B (zh) 包含4-1bbl之靶向her2的抗原結合分子
TW202227494A (zh) 多特異性免疫靶向分子及其用途
KR20220016945A (ko) 다중특이적 단백질
KR20180031728A (ko) 다가 및 다중특이적 gitr 결합 융합 단백질
JP2020512814A (ja) 免疫抱合体
CA2956126A1 (en) Sirp-alpha immunoglobulin fusion proteins
CN107250161A (zh) 包含dr5‑结合结构域的多价分子
JP2022531306A (ja) ＣＬＥＣ１２ａ結合性ポリペプチド及びその使用
JP2022531765A (ja) Ｃｄ３３結合性ポリペプチド及びその使用
CN111465618A (zh) 双特异性cd16-结合分子及其在疾病治疗中的用途
US20190077870A1 (en) Engineered trail for cancer therapy
JP2023524995A (ja) イヌｐｄ－１結合性ポリペプチド及びその使用
KR20190117467A (ko) IFN-γ-유도성 조절 T 세포 전환가능 항암 (IRTCA) 항체 및 그의 용도
KR20230024408A (ko) 항-cldn-18.2 항체 및 그 용도
RU2826084C2 (ru) МОЛЕКУЛЫ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТ PD-L1 и CD137
RU2777573C2 (ru) Антитела против 4-1bb человека и их применение
HK40130060A (en) Combination therapy with fap-targeted lymphotoxin beta receptor agonists
CN121358775A (zh) 利用靶向FAP的淋巴毒素β受体激动剂的组合疗法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181015

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200313

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20210305

WITB Written withdrawal of application